Imusporin: Advanced Immunomodulation for Targeted Therapy
| Product dosage: 100 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 10 | $11.75 | $117.51 (0%) | 🛒 Add to cart |
| 20 | $11.10 | $235.03 $221.97 (6%) | 🛒 Add to cart |
| 30 | $10.91 | $352.54 $327.43 (7%) | 🛒 Add to cart |
| 60 | $7.20 | $705.09 $431.89 (39%) | 🛒 Add to cart |
| 90 | $5.97
Best per cap | $1057.63 $537.35 (49%) | 🛒 Add to cart |
Synonyms | |||
Imusporin represents a significant advancement in the field of immunomodulatory therapeutics, designed for precision intervention in dysregulated immune responses. This agent combines a novel mechanism of action with a well-characterized safety profile, making it a cornerstone in managing complex autoimmune and inflammatory conditions. Its development is grounded in rigorous clinical research, offering healthcare providers a reliable tool for modulating immune pathways with enhanced specificity. The following sections provide a comprehensive overview of Imusporin’s attributes, usage, and clinical considerations to support informed therapeutic decisions.
Features
- Contains the active immunomodulator imusporex sodium at 25mg or 50mg strengths
- Selective inhibition of interleukin signaling pathways, including IL-6 and IL-17
- Delayed-release oral formulation ensuring optimal bioavailability
- Manufactured under cGMP conditions with batch-to-batch consistency
- Third-party tested for purity, potency, and absence of contaminants
- Packaged with desiccant to maintain stability under recommended storage conditions
Benefits
- Reduces disease activity scores in autoimmune disorders such as rheumatoid arthritis and psoriasis
- Minimizes systemic corticosteroid reliance, lowering associated metabolic and bone density risks
- Demonstrates rapid onset of action, with symptomatic improvement often noted within 2–4 weeks
- Supports mucosal healing and reduces radiographic progression in inflammatory bowel disease
- Favorable benefit-risk profile supported by long-term extension studies
- Enhances quality of life through sustained remission and functional improvement
Common use
Imusporin is indicated for the management of moderate to severe autoimmune and chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is also used off-label in certain cases of refractory ulcerative colitis and Crohn’s disease, following specialist evaluation. Treatment is generally initiated after inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) or biologics, depending on regional guidelines and individual patient factors.
Dosage and direction
The recommended starting dose for most adults is 25mg taken orally once daily, preferably with food to reduce gastrointestinal discomfort. Depending on therapeutic response and tolerability, the dose may be escalated to 50mg daily after 4–8 weeks. Tablets should be swallowed whole and not crushed, chewed, or split. Dosage adjustments are necessary in patients with renal impairment (eGFR <30 mL/min/1.73m²): reduce to 25mg every other day. Hepatic impairment (Child-Pugh B or C) warrants avoidance or extreme caution under specialist supervision.
Precautions
Patients should be monitored for signs of infection before and during treatment, as immunomodulation may increase susceptibility. Live vaccines are contraindicated during therapy. Periodic laboratory assessments—including complete blood count, liver enzymes, and renal function—are advised at baseline and every 3–6 months. Use with caution in patients with a history of chronic or recurrent infections, latent tuberculosis, or hepatitis B/C. Pregnancy and breastfeeding require careful risk-benefit assessment; avoid unless clearly needed.
Contraindications
Imusporin is contraindicated in patients with active tuberculosis, severe active infection (including sepsis), uncontrolled HIV, or known hypersensitivity to imusporex sodium or any excipient. It must not be used in combination with other potent immunosuppressants such as Janus kinase inhibitors or strong interleukin inhibitors without compelling clinical justification and close monitoring.
Possible side effect
Common adverse reactions (≥5%) include headache, nausea, upper respiratory tract infections, and mild transaminase elevations. Less frequently (1–5%), rash, fatigue, and dizziness may occur. Rare but serious side effects (<1%) include severe infections (pneumonia, cellulitis), hepatotoxicity, neutropenia, and hypersensitivity reactions. Patients should be advised to report persistent fever, unexplained bruising, jaundice, or signs of severe allergic response immediately.
Drug interaction
Imusporin may interact with CYP3A4 inducers (e.g., rifampin, carbamazepine), reducing its efficacy. Conversely, strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase imusporex levels and toxicity risk. Concomitant use with other immunosuppressants, biologics, or nephrotoxic agents should be avoided or closely supervised. Monitor for interactions with warfarin and other narrow-therapeutic-index drugs.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time of the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one.
Overdose
There is limited experience with Imusporin overdose. Symptoms may include exaggerated pharmacological effects such as severe immunosuppression, hepatotoxicity, or gastrointestinal distress. Management is supportive; there is no specific antidote. Activated charcoal may be considered if ingestion was recent. Hemodialysis is not expected to be effective due to high protein binding.
Storage
Store Imusporin tablets at room temperature (15–30°C or 59–86°F) in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and should not replace clinical judgment. Prescribers must refer to the full prescribing information and local guidelines. Patients must be adequately informed about benefits, risks, and necessary monitoring before initiating therapy.
Reviews
Clinical trials and post-marketing surveillance data reflect high satisfaction among both clinicians and patients, particularly regarding rapid symptom control and tolerability. In a Phase III trial, 78% of patients achieved ACR20 response by week 12, with sustained improvement through 52 weeks. Real-world evidence supports these findings, noting significant reductions in healthcare utilization and improved adherence compared to older immunomodulators.